EcoDrugPlus

Vitamin D Receptor

Ensembl ID : ENSCGOG00000023518
Gene Symbol: VDR
3 Cross references
392 Possible Orthologues:

Vitamin D3 Receptor B-Like

Ensembl ID : ENSCGOG00000000153
Gene Symbol: LOC115008607
3 Cross references
394 Possible Orthologues:

Vitamin K Epoxide Reductase Complex Subunit 1-Like Protein 1

Ensembl ID : ENSCGOG00000018642
Gene Symbol: LOC115025109
3 Cross references
191 Possible Orthologues:

Voltage-Dependent L-Type Calcium Channel Subunit Alpha-1d-Like

Ensembl ID : ENSCGOG00000015173
Gene Symbol: LOC115005436
3 Cross references
177 Possible Orthologues:

Voltage-Dependent L-Type Calcium Channel Subunit Beta-4-Like

Ensembl ID : ENSCGOG00000006066
Gene Symbol: LOC115010710
3 Cross references
203 Possible Orthologues:

Voltage-Dependent P/q-Type Calcium Channel Subunit Alpha-1a-Like

Ensembl ID : ENSCGOG00000021366
Gene Symbol: LOC115005468
3 Cross references
196 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-3 Subunit-Like

Ensembl ID : ENSCGOG00000003072
Gene Symbol: LOC115011390
2 Cross references
193 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-4 Subunit-Like

Ensembl ID : ENSCGOG00000010843
Gene Symbol: LOC115015593
3 Cross references
168 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-4 Subunit-Like

Ensembl ID : ENSCGOG00000011037
Gene Symbol: LOC115012819
3 Cross references
192 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-6 Subunit-Like

Ensembl ID : ENSCGOG00000010839
Gene Symbol: LOC115016186
3 Cross references
181 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-7 Subunit-Like

Ensembl ID : ENSCGOG00000010846
Gene Symbol: LOC115015805
3 Cross references
188 Possible Orthologues:

Voltage-Dependent Calcium Channel Subunit Alpha-2/delta-1-Like

Ensembl ID : ENSCGOG00000022290
Gene Symbol: LOC115028087
3 Cross references
230 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).